Avanza Fonder Ab Exact Sciences Corp Transaction History
Avanza Fonder Ab
- $3.37 Trillion
- Q4 2024
A detailed history of Avanza Fonder Ab transactions in Exact Sciences Corp stock. As of the latest transaction made, Avanza Fonder Ab holds 19,512 shares of EXAS stock, worth $844,674. This represents 0.03% of its overall portfolio holdings.
Number of Shares
19,512Holding current value
$844,674% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding EXAS
# of Institutions
673Shares Held
152MCall Options Held
4.25MPut Options Held
1.89M-
Capital World Investors Los Angeles, CA17.5MShares$759 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA17MShares$737 Million0.02% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$522 Million0.01% of portfolio
-
State Street Corp Boston, MA6.23MShares$270 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.76MShares$249 Million0.04% of portfolio
About EXACT SCIENCES CORP
- Ticker EXAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 176,960,000
- Market Cap $7.66B
- Description
- Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...